Olainfarm: Audited annual report 2020
The Company reviewed operations in the main markets
JSC Olainfarm continued investments to modernize its operations and worked on clinical trials
Group s revenues in 2020 were EUR 122,157 thousand, net profit was EUR 9,478 thousand.
Group actively engaged to improve operations and financial results of subsidiaries
In 2020, JSC Olainfarm approved its new strategy Forward! 2020-2025 . The main goal is to become one of the TOP 10 largest pharmaceutical manufacturing companies in Central and Eastern Europe by 2025, sustainably supplying healthcare products and services in specific therapeutic areas: cardiovascular diseases, neurology, psychiatry, and the treatment of urinary diseases. In 2020 Olainfarm Group continued the transformation process towards sustainable growth. Due to the Covid-19 pandemic, it was a year of challenges to remain operational efficient, where innovative ways of thinking to break the traditional way of conducting busin